Business context and reporting period
LeMaitre Vascular, Inc. develops, manufactures and sells medical devices used primarily in vascular surgery, and provides human-tissue processing and cryopreservation services. This Form 10-Q reports the quarter and nine months ended September 30, 2022; amounts below are in U.S. dollars unless noted.
Financial performance and position
- Revenue: Q3 net sales were $39.0 million, up 2% year over year; nine-month sales were $120.7 million, up 5%. Nine-month growth was led by bovine grafts, carotid patches, allograft services and shunts.
- Profit and margins: Q3 gross profit was $25.1 million and gross margin was 64.2%, versus 64.8% a year earlier. Operating income was $6.2 million versus $9.1 million; net income was $5.5 million versus $6.5 million, and diluted EPS was $0.25 versus $0.30. For nine months, gross margin was 65.3% versus 65.6%; operating income was $19.9 million versus $28.1 million; net income was $15.0 million versus $20.7 million; diluted EPS was $0.68 versus $0.98.
- Costs: Q3 operating expenses rose 20% to $18.9 million, as sales and marketing, general and administrative, and R&D costs increased. Nine-month operating expenses rose 25% to $59.0 million, including $3.1 million of restructuring costs related to the French factory closure.
- Cash flow: Nine-month operating cash flow was $21.3 million, down from $30.0 million. Working capital used $7.9 million, including a $5.0 million increase in inventory and deferred costs. Investing activities used $10.0 million; financing activities used $7.1 million, principally for dividends.
- Liquidity and debt: At September 30, cash and equivalents were $16.9 million and short-term marketable securities were $62.8 million, totaling $79.7 million. Current assets were $153.1 million and current liabilities $23.4 million. The company reported no outstanding long-term debt; its bank credit agreement had been terminated in November 2021. Lease liabilities totaled $16.7 million, including current and long-term amounts.
- Capital returns: The company paid $0.375 per share in dividends during the first nine months of 2022. A $20 million share-repurchase authorization was in place through February 22, 2023, but no repurchases had been made under it as of the filing; limited share withholding for employee taxes is reported separately.
Material changes versus the prior comparable period
- Revenue growth was modest in Q3, while operating and net income declined as operating expenses rose faster than sales. For the nine months, increased sales and gross profit were offset by higher operating costs and restructuring expense.
- Gross margin declined in both periods. Management cited higher labor costs, unfavorable product mix and currency movements, and manufacturing inefficiencies, including inventory write-offs.
- The stronger U.S. dollar reduced reported sales by an estimated $1.9 million in Q3 and $4.4 million for the nine months compared with prior-year exchange rates.
- Cash and equivalents increased from $13.9 million at December 31, 2021, while marketable securities increased from $56.1 million. The securities carried an unrealized loss of $2.1 million related to rising interest rates.
Outlook, commentary, risks and unusual items
- No specific full-year revenue or earnings guidance is provided. Management said cash, cash equivalents, investments and interest income are expected to cover anticipated cash needs for at least the next 12 months.
- Management’s strategy includes expanding direct sales, pursuing complementary acquisitions, growing product offerings, and consolidating manufacturing in Burlington. The company expects to transition Cardial graft sales to its Burlington-produced AlboGraft product, targeting cost savings and improved margins.
- The St. Etienne, France factory closed in June 2022. The closure generated $3.1 million of restructuring expense, with total closure costs expected to be approximately $3.5 million. The property was sold on October 10, 2022 for $0.9 million less closing costs, with an approximately $0.1 million gain.
- Regulatory transitions are a significant risk. The filing describes potential EU MDR and UKCA certification delays, including possible product backorders for CardioCel/VascuCel and the Pruitt F3 shunt. Regulatory timing, product restrictions and tissue-supplier availability could affect sales and margins.
- Other cited risks include unpredictable procedure volumes and hospital access related to COVID-19, foreign-exchange fluctuations, product demand and pricing, acquisition integration, and execution of the direct-sales strategy. The filing identifies no pending legal matter management believed would materially adversely affect financial position, results or cash flows.
- Unusual items include $1.4 million of nine-month loss on divestitures and a Q3 effective tax rate of 11.3%, which management attributed in part to tax benefits associated with the French factory closure.
Important facts for investors to verify
- Whether sales growth can outpace the faster growth in operating expenses and restore operating margins.
- Whether inventory, deferred costs and write-offs stabilize, and whether operating cash flow improves.
- Timing and impact of MDR/UKCA approvals, particularly for products exposed to potential backorders or supply constraints.
- Progress and actual savings from the Cardial factory closure and manufacturing transition, alongside any further transition costs.
- Foreign-exchange effects and the value and liquidity of the short-term marketable securities, including unrealized losses.
- Future dividend decisions, any share repurchases, and potential acquisition-related payments or other capital needs.